Vigil Neuroscience Inc. (VIGL)
Company Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases.
Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.
The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction.
Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. |
Contact Details
Address: 1 Broadway Cambridge, Massachusetts United States | |
| Website | https://www.vigilneuro.com |
Stock Details
| Ticker Symbol | VIGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001827087 |
| CUSIP Number | 92673K108 |
| ISIN Number | US92673K1088 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer & Director |
| Jennifer Ziolkowski CPA | Chief Financial Officer |
| April Effort M.B.A., M.S. | Vice President & Head of Corporate Development |
| Christian Mirescu Ph.D. | Senior Vice President & Head of Neuroimmunology |
| Dr. David Gray Ph.D. | Chief Scientific Officer |
| Eric Brophy | Senior Manager of Information Technology |
| Evan A. Thackaberry DABT, Ph.D. | Senior Vice President & Head of Early Development |
| Leah Gibson | Vice President of Investor Relations and Corporate Communications |
| Sharon Morani | Senior Director of Facilities & Operations |
| Weeteck Yeo Ph.D. | Senior Vice President of Strategic Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 23, 2025 | 8-K | Current Report |
| Dec 19, 2024 | 4 | Filing |
| Dec 19, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 05, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |